Login
$VBIO
$0.55 +$0.02 (4.18%) After hours

$VBIO 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

Fifth Side Letter — Closing under Series B Preferred Purchase Agreement

05 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation
02 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Certain personal information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. The omitted information is indicated by “[***]”

29 Oct 2026 8-K: Other Events

Valion Bio Announces Positive Safety Results from U.S. Government-Funded Entolimod Study, Paving Way for Therapeutic Efficacy Evaluation

27 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

Re: Fourth Side Letter — Closing under Series B Preferred Purchase Agreement

26 Oct 2026 8-K: Other Events

Unsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod

22 Oct 2026 8-K: Other Events

Interim CEO Dean Zikria’s initial review prioritizes Entolimod and pipeline advancement, commercialization of Velocity Bioworks, and strategic opportunities to maximize the value of the Company’s integrated capabilities

15 Oct 2026 8-K: Other Events

Velocity Bioworks successfully completes initial evaluation of LarmorBio’s BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of cell size, density, vi...

14 Oct 2026 8-K: Other Events

With Section 232 Tariffs Reshaping Biotech, Valion Bio’s Velocity Bioworks Capitalizes on Domestic CDMO Surge

08 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

Third Side Letter — Closing under Series B Preferred Purchase Agreement

06 Oct 2026 8-K: Other Events

Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data and wholly owned U.S. manufacturing

01 Oct 2026 8-K: Other Events

Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity

23 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

This CONSULTING AGREEMENT (this “Agreement”) with an effective date of September 22, 2026 (“Effective Date”) is made by and between Valion Bio, Inc. (the “Company” or “Valion”), and Dean Zikria (“Consultant”).

01 Sep 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.

27 Aug 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

SAN ANTONIO, TX – August 27, 2026 – Valion Bio, Inc. (Nasdaq: VBIO) (“Valion Bio” or the “Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company’s issued and outstanding shares of ...

17 Aug 2026 8-K: Unregistered Sales of Equity Securities; Departure/Election of Directors or Officers; Compensation +2 more

This ROYALTY AGREEMENT (this “Agreement”), dated as of August 17, 2026, is by and between Velocity Bioworks, Inc., a Delaware corporation (“VBI”), Valion Bio, Inc., a Delaware corporation (the “Parent,” and together with VBI, the “Payor ...

06 Aug 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

On July 31, 2026, the Company issued an aggregate of 1,287.8685 shares of Series A Preferred Stock (“Milestone Shares”), as consideration for the Milestone Payment (as discussed in more detail in Item 8.01 below), to Statera and Avenue V...

14 Jul 2026 8-K: Regulation FD Disclosure

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion

18 Jun 2026 8-K: Unregistered Sales of Equity Securities; Other Events

As previously announced, on April 29, 2025, Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) (the “Company”) entered into a Securities Purchase Agreement (as subsequent assigned and amended, the “Purchase Agreement”) with ...

03 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

WHEREAS, the Board of Directors and stockholders of Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) (the “Company”) have each adopted and approved the Valion Bio, Inc. Amended and Restated 2021 Equity Incentive Plan, as a...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support